The Return of Diphtheria
After decades of dormancy, diphtheria, a serious yet preventable illness, is re-emerging in parts of Australia, sparking concern among health officials.
Recent reports indicate outbreaks in the Northern Territory, with significant numbers of both respiratory and cutaneous diphtheria cases recorded since early 2025 and March 2026 respectively. Additionally, the Kimberly region of Western Australia has also seen cases this year. This resurgence is particularly noteworthy given that widespread vaccination efforts, which began in the 1930s, had rendered the disease exceptionally rare in Australia by the 1950s. A stark reminder of diphtheria's potential severity was also observed in Rajasthan's Deeg in 2024, where an outbreak tragically claimed the lives of seven children, underscoring the fatal consequences of immunisation gaps and delayed medical attention in vulnerable communities.
Understanding Diphtheria's Spread
Diphtheria, a contagious bacterial infection caused by Corynebacterium diphtheriae, primarily targets the throat and upper respiratory tract, producing a potent toxin that can lead to severe damage to the heart and nervous system. The bacteria propagate through respiratory droplets expelled by infected individuals when they cough or sneeze. Transmission can also occur through close personal contact. Interestingly, some carriers may exhibit no disease symptoms but can still transmit the bacteria to others. In other instances, individuals may experience mild illness, but severe complications and even fatalities are possible. While diphtheria can affect anyone, it was historically most prevalent among unvaccinated children. Experts attribute its recent reappearance to declining vaccination coverage, waning immunity in adults who have not received booster doses, and the increased prevalence of global travel, which facilitates the bacteria's circulation across different regions.
Recognizing Early Symptoms
The initial indicators of diphtheria often mimic those of common respiratory infections, presenting as a sore throat, a mild fever, and general fatigue. However, a distinctive hallmark of the disease is the development of a thick, greyish membrane that forms over the throat or tonsils, posing a significant risk of obstructing the airway and impeding breathing. Affected individuals may also experience swelling of the neck glands, sometimes described as a 'bull neck' appearance. In cases of cutaneous diphtheria, the symptoms manifest as persistent, non-healing skin ulcers that are covered by a characteristic dirty grey membrane. The progression of diphtheria can be alarmingly swift and systemic due to the rapid action of the produced toxin, making prompt identification absolutely crucial for effective intervention.
Treatment and Prevention
Medical interventions for diphtheria are highly effective when administered promptly. The cornerstone of treatment involves the administration of diphtheria antitoxin, which works to neutralize the circulating toxin. Complementing this, antibiotics, such as penicillin or erythromycin, are prescribed to eradicate the bacteria and prevent further spread. It is critical to note, however, that these treatments cannot reverse damage already inflicted by the toxin, emphasizing the paramount importance of early medical intervention. Vaccination stands as the most robust method of prevention, with childhood immunisation programs providing substantial protection. Booster doses administered during adolescence and adulthood are essential for maintaining ongoing immunity. Achieving high vaccination coverage within a community not only safeguards individuals but also significantly curtails the disease's transmission, which is the most effective strategy for preventing widespread outbreaks.
India's Proactive Measure
In light of the global threat posed by diphtheria and similar vaccine-preventable diseases, India has bolstered its vaccination initiatives. The Union Health Minister recently launched an indigenously developed Tetanus and Adult Diphtheria (Td) vaccine. This new vaccine is specifically designed to enhance immunisation rates among adults, thereby reducing their susceptibility to infections like diphtheria. This development is a significant step towards fortifying public health defenses and ensuring greater protection against diseases that, while once thought controlled, demonstrate a persistent capacity to resurface and cause harm, particularly in populations with lower immunisation coverage.
